Glioma is one of the common tumors in the central nervous system. Its treatment methods， which include surgery， radiotherapy， and drug chemotherapy， lack specificity， and the prognosis of patients is poor after treatment. With the development of immunology， cell biology， and genomics， tumor immunotherapy has ushered in a new era of tumor therapy. It has achieved significant results in other invasive cancers， such as advanced melanoma and advanced non-small cell lung cancer. At present， the basic and clinical trials of immunotherapy in glioma are also progressing rapidly. This article summarizes the promising methods of immunotherapy in recent years， and it reviews the current status of preclinical and clinical trials and discusses the challenges and future prospects of glioma immunotherapy. ［Journal of International Neurology and Neurosurgery, 2023, 50(3): 73-77］